ArticleScientific reports2025
Integrated analysis of single-cell and bulk RNA-sequencing to predict prognosis and therapeutic response for colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modulation of intestinal bile acids influences colonic mucosal responses.Scientific reports · 2026Article
- An integrated bulk and single-cell transcriptomic analysis reveals stemness-driven immune regulation and therapeutic vulnerability in colorectal cancer.Journal of Cancer · 2026Article
- Single-cell RNA sequencing defines prognostic subtypes and identifies AIF1L as a therapeutic target in colorectal cancer.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a prevalent malignant tumor characterized by high global incidence and mortality rates. Furthermore, it is imperative to comprehend the molecular mechanisms underlying its development and to identify effective prognostic markers. These efforts are crucial for pinpointing potential therapeutic targets and enhancing patient survival rates. Therefore, we develop a novel prognostic model aimed at providing new theoretical support for clinical prognosis evaluation and treatment. We downloaded data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Subsequently, we performed single-cell analysis and developed a prognostic model associated with colorectal cancer. We divided the scRNA-seq dataset (GSE221575) into 19 cell clusters and classified these clusters into 11 distinct cell types using marker genes. Using univariate Cox regression and LASSO (Least Absolute Shrinkage and Selection Operator) analyses, we developed a prognostic model consisting of 9 genes. Based on our 9-gene model, we divided patients into high-risk and low-risk groups using the median risk score. The high-risk group demonstrated significant positive correlations with M0 macrophages, CD8+ T cells, and M2 macrophages. The enrichment analyses indicate significant enrichment of immune-related pathways in the high-risk group, including HEDGEHOG_SIGNALING, Wnt signaling pathway, and cell adhesion molecules. Drug sensitivity analysis revealed that the low-risk group was sensitive to 5 chemotherapeutic drugs, while the high-risk group was sensitive to only 1. Additionally, we developed a highly reliable nomogram for clinical application. This suggests that the risk score derived from our modeling analysis is highly effective for stratifying colorectal cancer samples. This study comprehensively applied bioinformatics methods to construct a risk score model. The model showed good predictive performance, offering potential guidance for individualized treatment of colorectal cancer patients. Furthermore, it may provide valuable insights into the disease's pathogenesis and identify potential therapeutic targets for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.